# Establishing a Dedicated Fund to Improve Patient Access to Cancer Medicines: Key Considerations and Policy Implications for Thailand: Comment on "Scoping Review of International Experience of a Dedicated Fund to Support Patient Access to Cancer Drugs: Policy Implications for Thailand"

## TL;DR

The paper discusses how Thailand can create a cancer drug fund to improve patient access while balancing innovation, affordability, and fairness.

## Contribution

It proposes a structured framework for designing a cancer drug fund aligned with Thailand's socioeconomic and policy systems.

## Key findings

- A cancer drug fund should be designed with measurable clinical benefits and cost-effectiveness in mind.
- Cost-ineffective but life-saving drugs need fair and transparent inclusion strategies.
- Robust governance and evaluation frameworks are essential for the success of the fund.

## Abstract

Thai policy-makers should carefully design a well-structured, managed-access cancer drug fund (CDF) that aligns with the country’s socioeconomic system and complements existing institutional and policy frameworks. Developing this framework requires a clear and evidence-based definition of innovative cancer drugs, grounded in measurable clinical benefits such as overall survival (OS) and cost-effectiveness. It also requires careful consideration of alternative policies to address the challenges posed by high-priced cancer drugs. In addition, strategies are needed to incorporate cost-ineffective yet life-saving drugs with no therapeutic alternatives into the healthcare system in a fair and transparent manner. It also requires rigorous evaluation of the effectiveness of the CDF, supported by empirical evidence and underpinned by robust operational and data governance frameworks. Such a framework could serve as a foundation for Thailand’s future efforts to balance innovation, affordability, and equity in cancer care.